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Abstract The aims of the present study are to describe the
characteristics of rheumatoid arthritis (RA) patients selected
for tocilizumab (TCZ), compare the Breal-world^ effective-
ness of TCZ and tumour necrosis factor inhibitors (TNFi)
when used as a first biologic and assess the influence of past
biologic exposure/concurrent methotrexate (MTX) therapy on
post-TCZ treatment outcomes. The British Society for
Rheumatology Biologics Register (BSRBR-RA) is a prospec-
tive cohort study following RA patients starting biologics in
the UK. This includes patients starting TCZ as first or subse-
quent biologic, alongside biologic-naïve patients starting
TNFi. Six-month disease activity and 1-year drug survival
were compared between biologic-naïve patients starting
TCZ versus TNFi and first-line versus subsequent TCZ users
and TCZ users with MTX versus without using regression
models adjusted by propensity score. Two hundred seventeen
patients started TCZ, and 2419 started TNFi as first biologic.
Seven hundred seventy-seven started TCZ after other bio-
logics. First-line TCZ users had a higher prevalence of pul-
monary fibrosis and cancer history than TNFi users. The first-
line TCZ users were more likely to achieve DAS28 remission
at 6 months than first-line TNFi, but other improvement
markers were similar. The treatment response at 6 months
was similar between subsequent-line TCZ users and first-
line users after adjusting for baseline patient differences.
Concurrent MTX use was not associated with treatment re-
sponse in either first- or subsequent-line TCZ users. TCZ has
been primarily used as subsequent-line biologic in the UK.
When used as first line, the response appears similar to that
observed in patients starting TNFi, suggesting that clinical
response alone should not decide between initial biologic
therapies.
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Introduction
Cytokines such as tumour necrosis factor (TNF)-α, interleu-
kin (IL)-1 and IL-6 play a fundamental role in the pathogen-
esis of rheumatoid arthritis (RA) [1]. Biological disease-
modifying anti-rheumatic drugs (bDMARDs) targeting these
cytokines have resulted in improved outcomes among patients
with RA resistant to traditional synthetic DMARD
(sDMARDs). Drugs which inhibit TNF (tumour necrosis
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factor inhibitors (TNFi)) were the first available biologic ther-
apies [2], but the choice has expanded, and since 2010, toci-
lizumab (TCZ), a humanised monoclonal antibody against the
IL-6 receptor, has been available for use in RA. In the UK, the
drug is approved by the National Institute for Health and Care
Excellence (NICE) for use both as a first-line biologic therapy
after failure of two sDMARDs and as a subsequent-line bio-
logic therapy after failure of TNFi in patients with severe RA
(DAS28 >5.1) [3–5].
With an expanding choice of biologic therapies for use in
patients resistant to sDMARDs, there is little information on
how these therapies are being selected in clinical practice, as
well as a lack of data regarding comparative effectiveness
between therapies to help clinicians guide choice of therapies.
There also has been little evidence from routine care regarding
the factors associated with the optimal effectiveness of TCZ.
For example, the impact of prior bDMARD exposure history
and concomitant use of methotrexate (MTX) on the effective-
ness of TCZ have not been assessed sufficiently.
Whilst a randomised controlled trial (RCT) (ADACTA
study) suggested the superiority of TCZ monotherapy in re-
ducing DAS28 compared to anti-TNF adalimumab (ADA)
monotherapy among bDMARD-naïve patients with inade-
quate response to MTX [6], there have been no other RCTs
comparing the efficacy of TCZ with TNFi directly. Three
cohort studies (two retrospective and one prospective) have
compared the effectiveness of TCZ and TNFi, which also
suggested the superiority of TCZ [7–9]; however, there is a
lack of large comparative effectiveness studies in routine clin-
ical settings.
There is also limited or inconsistent information regarding
factors associated with better response to TCZ. Recent pro-
spective studies of patients who started TCZ have suggested
that TCZ may be more effective for patients when used as a
first biologic compared to those patients receiving the drug
after failure of other biologics [10–12]. While evidence has
suggested that TNFi may be more effective when used in
combination with MTX, this is less clear for TCZ. Two clin-
ical trials (the ACT-RAY study and the SURPRISE study) and
three cohort studies suggested that concomitant MTX may
lead to favourable treatment outcomes [10, 13–16]; however,
a retrospective study, a European collaborative study and
ACT-LIFE study from routine clinical settings suggested no
difference in effectiveness of TCZ when combined with MTX
[11, 13, 17, 18]). Limited evidence from routine use is cur-
rently available.
Further information regarding the Breal-world^ effective-
ness of TCZ when used at different points in the RA treatment
pathway will provide better evidence on which to frame
healthcare decisions. The aims of this analysis are therefore
to (1) describe characteristics of patients with RA selected for
TCZ in the UK, (2) compare the real-world effectiveness of
TCZ to TNFi over the short term (first 6 months) when used as
a first biologic and (3) assess the influence of concurrentMTX
therapy and past biologic exposure on short-term treatment
outcomes following TCZ.
Methods
Patients The British Society for Rheumatology Biologics
Register for RA (BSRBR-RA) is a national prospective cohort
study collecting information on patients aged 16 or older with
a physician’s diagnosis of RA starting biologic therapies. This
analysis included all either patients registered with the
BSRBR-RA starting TCZ (either as their first biologic (first-
line TCZ cohort) or those who had already received biologic
therapies and were switching to TCZ (subsequent-line TCZ
cohort) or starting TNFi therapy (etanercept—Enbrel (ETN),
infliximab—Remicade (IFX), adalimumab—Humira (ADA)
or certolizumab pegol—Cimzia (CZP)) as their first biologic
between 01 January 2010 and 30 November 2015.
Baseline dataAt the start of bDMARD therapy, baseline data
were collected from the hospital including patient demo-
graphics; smoking status (current smoker/ex- or never smok-
er); height (cm) and weight (kg) to calculate body mass index
(BMI) (kg/m2); disease duration (years); past and current anti-
rheumatic therapies; rheumatoid factor (RF) status; extra-
articular manifestations of RA (EARA) including pulmonary
fibrosis, sicca syndrome, serosal involvement (pleuritic/peri-
carditis), eye involvement, systemic vasculitis and other spec-
ified systemic features based on physicians diagnosis; 28
swollen and tender joint counts (SJC, TJC); patients global
assessment visual analogue scale (VAS) (0–100 mm) erythro-
cyte sedimentation rate (ESR) (mm/h); and/or C-reactive pro-
tein (CRP) (mg/dl). Ever existence of comorbidities (hyper-
tension, angina, myocardial infarction, stroke, epilepsy, asth-
ma, chronic bronchitis/emphysema, peptic ulcer, liver disease,
renal disease, tuberculosis, demyelination, diabetes, hyperthy-
roidism, depression or cancer) was captured using a tick list. A
list of current medications was also obtained, and statin use
was used as a surrogate for baseline hyperlipidaemia. In addi-
tion, a comprehensive history of prior cancer was obtained
through linkage to the UK national cancer register. Patients
complete the Health Assessment Questionnaire (HAQ)
adapted for UK use [19].
Follow-up data Follow-up data were captured from the hos-
pital and patient every 6 months for 3 years and then annually
from the hospital only. Hospital data include the most recent
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DAS28 and changes to anti-rheumatic therapy including stop
reasons and adverse events. Patients complete a HAQ.
Data analysis This study compared the baseline characteris-
tics and treatment effectiveness at 6 months between the (1)
first-line TCZ cohort versus first-line TNFi cohort, (2) first-
line TCZ cohort versus subsequent-line TCZ cohort and (3)
first-line/subsequent-line TCZ users with and without con-
comitant MTX. All data available up to 31 May 2016 were
included.
Treatment effectiveness at 6 months was described
using the following measures: change in DAS28 and its
components, European League Against Rheumatism
(EULAR) response [20], DAS28 remission [21], change
in HAQ score, the proportion of patients who achieved
the minimal clinically important difference (MCID) in
HAQ, defined as a ≥0.22 decrease in score [22] and the
drug retention rates up to year 1. DAS28 was calculated
using the ESR where available. However, if only a CRP
measurement was provided (27% of patients), the DAS28-
CRP [23] was calculated instead (online Supplementary
Table 1). Non-parametric descriptive statistics were used
to compare baseline characteristics between cohorts.
Regression models were used to compare EULAR re-
sponse (ordinal models) and DAS28 remission (logistic
regression) between treatments. Each regression model
was adjusted by (1) age and sex and (2) the estimated
propensity score using inverse probability of treatment
weighting (IPTW) without trimming. [24] The propensity
score was determined separately for each comparison. To
estimate each propensity score, logistic regression models
including factors showing significant differences between
cohorts at baseline and the factors that may predict changes
in outcome were constructed. Drug survival up to year 1
was described using Kaplan-Meier curves and compared
using the log-rank test.
Missing data were accounted for in regression models
using multiple imputation, using the mi package in Stata with
20 iterations. Information regarding missing data is included
in online Supplementary Table 1. When it was not possible to
calculate the DAS28 due to one or more missing components,
the DAS28 score itself was imputed. All analyses were per-
formed using Stata (StataCorp 2013, Stata Statistical
Software: Release 13, College Station, TX: StataCorp LP).
Results
From 01 January 2010 until 30 November 2015, 2636 patients
registered with the BSRBR-RA starting their first biologic
(217 TCZ; 2419 TNFi: 884 ETN, 51 IFX, 542 ADA, 942
CZP), and 777 patients registered starting TCZ as a subse-
quent biologic therapy.
Comparison of baseline characteristics and treatment
effectiveness between patients starting first-line TCZ
or first-line TNFi following inadequate response
to sDMARDs
In general, there were few differences between patients
starting TCZ or TNFi as first-line biologic therapy (Table 1).
Noted differences largely reflected background comorbidity: a
history of pulmonary fibrosis was higher in the TCZ group
compared to TNFi (5 vs 2%, p = 0.001), as was prior cancer (9
vs 5%, p = 0.001). The proportion ofMTX use at baseline was
similar between the two cohorts, but the TCZ cohort had a
slightly lower percentage of previous MTX use (94 vs 96%,
p = 0.05). The TCZ cohort had lower VAS score (72 vs
78 mm, p = 0.002), but the disease activity according to
DAS28 was similar to the TNFi cohort (6.2 vs 6.0, p = 0.18).
Compared with the first-line TNFi cohort, the first-line
TCZ cohort showed significantly lower DAS28 at 6 months
(3.0 vs 3.5, p = 0.003) (Table 2) and higher absolute change in
DAS28 (2.9 vs 2.4, p < 0.001). The percentage of good re-
sponders was slightly higher in the TCZ cohort than in the
TNFi cohort (49 vs 42%); however, after adjustment using
IPTW by propensity score, there was no difference in odds
of achieving a higher EULAR response category. The percent-
age of patients who achieved DAS28 remission was higher in
the first-line TCZ cohort compared to the TNFi cohort (42 vs
28%, p < 0.001), which remained significant after adjustment
(adjusted odds ratio (OR) 1.86 (1.25–2.78)). However, an anal-
ysis of the individual components of DAS28 showed that the
reduction in ESR was greater with TCZ (median ESR change
16.0 vs 7.0 mm/h, p < 0.001), but changes were similar in the
other components of the DAS28 (online Supplementary Table 2).
HAQ score and the proportion with MCID achievement at
6 months were also similar between the two cohorts (Table 2).
Drug survival curves are shown in Fig. 1. The estimated 1-year
survival was 0.67 (95% CI 0.65–0.69) for first-line TNFi users
and was 0.77 (95% CI 0.70–0.82) for the first-line TCZ users.
This difference was not statistically significant (p = 0.20).
Comparison of baseline characteristics and treatment
effectiveness between patients starting TCZ as a first-line
versus subsequent-line biologic
Compared with the first-line cohort, the subsequent-line co-
hort had a significantly longer disease duration (12 vs 4 years,
p < 0.001), slightly better disease activity (median DAS28 5.7
vs 6.2, p < 0.001) and lower functional capacity (median HAQ
2.0 vs 1.6, p < 0.001) (Table 1). There were higher proportions
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of any extra-articular manifestations (30 vs 15%, p < 0.001),
any comorbidities (73 vs 62%, P = 0.003), reported depres-
sion (29 vs 20%, p = 0.001), hypertension (37 vs 25%,
p = 0.003) and joint replacement surgery history (30 vs
15%, P < 0.001), but the proportions of pulmonary fibrosis
were similar. Among subsequent-line TCZ cohort, most












Age, median (IQR) 57 (48–66) 58 (49–66) 0.7 58 (49–66) 0.77
Female, no. (%) 1833 (76) 159 (73) 0.4 616 (79) 0.06
Current smokers, no. (%) 472 (20) 42 (20) 0.9 93 (19) 0.9
BMI, median (IQR) 27.4 (23.7–32.0) 28.4 (24.7–32.0) 0.08 27.7 (24.0–32.9) 0.4
Disease characteristics
Disease duration (years), median (IQR) 5 (2–13) 4 (2–12) 0.2 12 (6–20) <0.001
RF positive, no. (%) 1331 (60) 121 (62) 0.7 282 (63) 0.8
Swollen joint count, median (IQR) 8 (5–12) 9 (6–13) 0.05 6 (3–10) <0.001
Tender joint count, median (IQR) 14 (9–20) 15 (9–22) 0.6 12 (7–20) 0.001
ESR (mm/h), median (IQR) 24 (12–40) 26 (13–45) 0.4 25 (10–45) 0.4
CRP(mg/dl), median (IQR) 11 (5–26) 13 (5–34) 0.2 13 (5–34) 0.8
Global health VAS score, median (IQR) 78 (62–89) 72 (55–85) 0.002 72 (56–84) 0.8
DAS28, median (IQR) 6.0 (5.4–6.6) 6.2 (5.3–6.8) 0.18 5.7 (5.0–6.4) <0.001
HAQ, median (IQR) 1.6 (1.0–2.1) 1.6 (1.1–2.1) 0.9 2.0 (1.6–2.4) <0.001
Joint replacement surgery history, no. (%) 509 (21) 40 (19) 0.4 168 (35) <0.001
Comorbidity status
Any EARAc, no. (%) 431 (18) 32 (15) 0.2 148 (30) <0.001
Pulmonary fibrosis, no. (%) 35 (2) 10 (5) 0.001 31 (6) 0.4
Any comorbiditiesd, no. (%) 1469 (61) 135 (62) 0.7 564 (73) 0.003
Hypertension history, no. (%) 685 (29) 53 (25) 0.2 279 (37) 0.001
Depression history, no. (%) 484 (21) 42 (20) 0.8 220 (29) 0.007
Diabetes history, no. (%) 173 (7) 22 (10) 0.1 63 (8) 0.3
Hyperlipidaemia history, no. (%) 402 (17) 38 (18) 0.7 178 (23) 0.09
Ischaemic heart disease history, no. (%) 133 (6) 17 (8) 0.1 57 (8) 0.8
Cancer history, no. (%) 123 (5) 20 (9) 0.001 69 (9) 0.8
Current and previous drug history
Number of previous sDMARDs, median
(IQR)
3 (2–3) 3 (2–3) 0.16 3 (2–4) 0.1
Current MTX, no. (%) 1566 (65) 136 (63) 0.5 496 (65) 0.6
Previous MTX, no. (%) 2323 (96) 203 (94) 0.05 737 (95) 0.3
Current steroids, no (%) 566 (23) 39 (18) 0.07 289 (37) <0.001
After 1 bDMARD, no. (%) 217 (28)
After 2 bDMARDs, no. (%) 321 (41)
After 3 or more bDMARDs, no. (%) 237 (31)
Statistically significant differences are given in italics
a Comparing between first-line TNFi users versus first-line TCZ users
b Comparing between first-line TCZ users versus subsequent-line TCZ users
c Extra-articular manifestations of rheumatoid arthritis (EARA)) including pulmonary fibrosis, sicca syndrome, serosal involvement (pleuritis/pericar-
ditis), eye involvement, systemic vasculitis, nailfold vasculitis and other specified systemic features
d Comorbidities included one or more of high blood pressure, angina, heart attack, stroke, epilepsy, asthma, chronic bronchitis/emphysema, peptic ulcer,
liver disease/hepatitis B or C, renal disease, tuberculosis, demyelination, diabetes, hyperthyroidism, depression or cancer
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patients had received two or more prior bDMARDs (41% had
two, 31% had three or more). Ninety-three percent had re-
ceived at least one prior TNFi, and 55% had also received
rituximab.
Compared to the first-line TCZ cohort, a lower proportion
of the subsequent-line cohort achieved good EULAR re-
sponses and DAS28 remission (Table 2). However, after
adjusting using IPTW by propensity score, there was no sig-
nificant difference in the odds of achieving either better
EULAR response or DAS28 remission between groups. In
the subsequent-line cohort, change in HAQ score at 6 months
was significantly smaller than in the first-line cohort (median
delta HAQ 0.0 vs 0.3, p = 0.002) and a lower percentage of
patients who achieved MCID (34 vs 49%, p < 0.001). Up to
year 1, the drug retention rate for the subsequent-line TCZ
Table 2 Changes in disease activity, disability and treatment response at 6 months following start of therapy
First-line TNFi
cohort (N = 2419)
First-line TCZ
cohort (N = 217)
P valuea Subsequent-line
TCZ cohort (N = 777)
P valueb
DAS28 at month 6 (N = 1764) (N = 158) 0.003 (N = 528) 0.01
Median (IQR) 3.5 (2.5–4.7) 3.0 (1.8–4.6) 3.5 (2.5–4.7)
EULAR response at month 6 (N = 1762) (N = 158) 0.2 (N = 527) 0.03
Good response, no. (%) 737 (42) 77 (49) 196 (37)
Moderate response, no. (%) 665 (38) 52 (33) 198 (38)
No response, no. (%) 360 (20) 29 (18) 133 (25)
DAS28 remission at month 6 (N = 1764) (N = 158) <0.001 (N = 528) 0.001
No. (%) 496 (28) 66 (42) 148 (28)
OR for better EULAR response at month 6 (N = 2419) (N = 217) (N = 777)
Unadjusted OR for better EULAR response (95% CI) Referent 1.14 (0.85, 1.52) 0.70 (0.51, 0.94)
Referent
Fully adjusted by IPTW OR for better
EULAR response (95% CI)c
Referent 1.33 (0.92, 1.94) 0.73 (0.47, 1.15)
Referent
OR for DAS28 remission at month 6 (N = 1627) (N = 116) (N = 589)
Unadjusted OR for DAS28 remission (95% CI) Referent 1.62 (1.19, 2.22) 0.61 (0.43, 0.86)
Referent
Fully adjusted by IPTW OR for DAS28 remission (95% CI)c Referent 1.86 (1.25, 2.78) 0.59 (0.34, 1.00)
Referent
HAQ at month 6 (N = 1167) (N = 100) 0.9 (N = 316) <0.001
Median (IQR) 1.4 (0.6–1.9) 1.3 (0.8–1.9) 2.0 (1.4–2.4)
Delta HAQ (baseline–month 6) (N = 968) (N = 88) 0.2 (N = 272) 0.002
Median (IQR) 0.1 (−0.1 to 0.5) 0.3 (−0.1 to 0.6) 0.0 (−0.1, 0.3)
MCIDd (N = 968) (N = 88) 0.2 (N = 241) <0.001
No. (%) 462 (48) 49 (46) 92 (34)
Statistically significant differences are given in italics
a Comparing between first-line TNFi users versus first-line TCZ users
b Comparing between first-line TCZ users versus subsequent-line TCZ users
c Variables in propensity score for comparing between first-line TNFi users and TCZ users included age, gender, disease duration, BMI, DAS28 at
baseline, HAQ score at baseline, concomitant use of MTX and steroids, current steroid, previous MTX use, pulmonary fibrosis presence, cancer history
and any extra-articular manifestation presence. For comparing first-line TCZ users and subsequent-line TCZ users, any comorbidities’ presence was
included instead of precious MTX use, pulmonary fibrosis presence and cancer history
dMCID was defined as a ≥0.22 decrease in HAQ score
Fig. 1 Drug survival curves of the first-line TNFi cohort, the first-line
cohort and the subsequent-line TCZ cohort
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users was estimated to be 0.71 (95% CI 0.67–0.74), which
was similar to the first-line TCZ users (p = 0.23) (Fig. 1).
Association between concurrent MTX use and response
to TCZ
Within patients starting TCZ either as first or subsequent-line
therapy, those who receive concomitant MTX therapy were
younger and had fewer extra-articular manifestations and pul-
monary fibrosis (online Supplementary Table 3).
After adjustment using propensity score, no significant
difference in the proportion who met the EULAR response
criteria or DAS28 remission was observed between MTX
users and non-users, both in the first-line and subsequent-
line cohorts, although low numbers in the first-line cohort
resulted in wide confidence intervals (Table 3). At
6 months, functional activities were also similar between
the cohorts. The drug survival curves were also similar
between patients receiving TCZ with and without concom-
itant MTX therapy (Fig. 2a, b). The retention rates were
estimated to be 0.77 (95% CI 0.68–0.84) for the first-line
TCZ users with MTX and 0.76 (95% CI 0.62–0.85) for
TCZ monotherapy (p = 0.10), 0.70 (95% CI 0.66–0.74)
for the subsequent-line TCZ users with MTX and 0.70
(95% CI 0.64–0.76) for TCZ monotherapy (p = 0.50),
respectively.
Table 3 Treatment response comparison between the MTX users versus non-users
First-line TCZ users P
valuea











DAS28 at baseline (N = 136) (N = 81) 0.03 (N = 496) (N = 270) 0.4
Median (IQR) 6.3 (5.5–6.9) 5.8 (5.2–6.6) 5.7 (5.0–6.4) 5.7 (4.9–6.5)
DAS28 at month 6 (N = 107) (N = 51) 0.04 (N = 357) (N = 166) 0.5
Median (IQR) 2.9 (1.6–4.3) 3.4 (2.2–5.0) 3.4 (2.5–4.6) 3.5 (2.4–5.0)
EULAR response at month 6 (N = 107) (N = 51) 0.2 (N = 356) (N = 166) 0.8
Good response, no. (%) 57 (53) 20 (39) 135 (38) 59 (36)
Moderate response, no. (%) 34 (32) 18 (35) 133 (37) 62 (7)
No response, no. (%) 16 (15) 13 (26) 88 (25) 45 (27)
DAS28 remission at month 6 (N = 107) (N = 51) 0.03 (N = 357) (N = 166) 0.7
No. (%) 51 (48) 15 (29) 98 (27) 48 (29)
OR for better EULAR response at month 6 (N = 107) (N = 51) (N = 356) (N = 166)












OR for DAS28 remission at month 6 (N = 107) (N = 51) (N = 357) (N = 166)













HAQ at month 6 (N = 67) (N = 33) 0.4 (N = 213) (N = 101) 0.3
Median (IQR) 1.4 (0.8–2.0) 1.1 (0.8, 1.8) 1.9 (1.4–2.3) 2.0 (1.4–2.4)
Delta HAQ (baseline–month 6) (N = 57) (N = 31) 0.5 (N = 181) (N = 89) 0.7
Median (IQR) 0.3 (−0.1 to 0.6) 0.4 (−0.1, 0.9) 0 (−0.1 to 0.3) 0.1 (−0.1 to 0.3)
MCIDd (N = 57) (N = 31) 0.2 (N = 181) (N = 89) 0.9
No. (%) 29 (51) 20 (64) 61 (34) 31 (35)
Statistically significant differences are given in italics
a Comparing between first-line TCZ users with MTX versus without it
b Comparing between subsequent-line TCZ users with MTX versus without it
c Variables in propensity score for first-line TCZ users included age, gender, disease duration, BMI, DAS28 at baseline, HAQ score at baseline,
concomitant steroid use, previous MTX use, pulmonary fibrosis presence, ischaemic heart disease presence, any EARA presence and number of
previous sDMARDs. For subsequent-line TCZ users, hypertension presence and depression presence were included instead of ischaemic heart disease
presence
dMCID was defined as a ≥0.22 decrease in HAQ score
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Discussion
This is the first study both to describe the clinical characteris-
tics of patients selected to receive TCZ as a first-line therapy in
routine clinical use and to examine its effectiveness as a first-
line and subsequent-line therapy. A majority of patients (78%
of TCZ cohort) were starting this treatment as a subsequent-
line biologic in the UK. In part, this may reflect the timing of
UK approvals for use, which did not extend to first-line use
until 2012, although even after this date, the majority of pa-
tients recruited were not starting TCZ as a first-line therapy.
Although similar with respect to disease history and disease
activity, compared to patients starting TNFi as their first bio-
logic, there were apparent differences in the comorbidity pro-
file of patients starting TCZ, which may have influenced the
choice of therapy. This was most noted with histories of pul-
monary fibrosis and cancer. Although recent studies with long
follow-up periods suggest that patients using TNFi are not at
increased risk of interstitial pneumonia [25] or cancer devel-
opment [26], several prior studies had indicated a possible link
between TNFi usage and increasing risk of developing
interstitial pneumonia and/or cancer [27–29] and both are in-
cluded as relative contraindications to TNFi in current UK
guidelines [29]. Despite the possible association between
TCZ use and increases in fasting lipid levels found during
clinical trials [30], we did not see any difference in baseline
history of hyperlipidaemia or cardiovascular disease.
This analysis has suggested a superior effectiveness of
TCZ compared to TNFi as a first bDMARD, particular in
relation to the proportion of patients who achieved DAS28
remission. These results are similar to the ADACTA study
(40% remission in the first-line TCZ users vs 11% in first-
line ADA users) [6] and a retrospective study from Germany
(44% in first-line TCZ users vs 30% in first-line TNFi users)
[7]. A national registry in Portugal showed higher percentage
of DAS remission in a first-line TCZ cohort (71% in first-line
TCZ users vs 24% in first-line TNFi users, p < 0.001) [9].
However, it is possible that the significantly higher percentage
of DAS28 remission achievement of TCZ users is explained
through differences in the effects of each therapy in lowering
the ESR and/or CRP, as when we compared the change in
each DAS component between the first-line TCZ users and
TNFi users, the improvements on the other components of
DAS28 (SJC, TJC and patient VAS) were similar. A single-
centre registry in Japan reported similar results in that patients
who achieved DAS28 remission with TCZ showed lower
mean ESR but, in fact, higher swollen joint counts [32].
Further studies focusing on other measures of inflammation
besides the DAS28, such as improvements in synovitis as
measured by ultrasound, are warranted. Whether this greater
improvement in ESR is clinically important in terms of long-
term clinical and radiographic outcomes, independent from
improvements in swollen joint count, is not known. As anoth-
er measure of effectiveness, we compared drug survivals of
first-line TNFi and TCZ. Although there was a trend towards
better survival with TCZ, this did not reach statistical signifi-
cance. In addition, the analysis was not adjusted for baseline
differences between patients because of the small quantity of
data, and therefore, no conclusions can be drawn about the
superiority of one drug over another in the longer term.
The majority of the patients in this study starting TCZ did
so after one or more other biologic therapies, with many hav-
ing failed >1. This will in part reflect the timing of introduc-
tion of different biologics into clinical practice. The ACT-
LIFE study in routine clinical setting suggested that TCZ
works better when used as a first-line therapy than as a subse-
quent line [11]. Our data also showed that the absolute pro-
portion of patients achieving a good EULAR response among
subsequent-line TCZ users was less than that seen among
first-line users. However, after adjusting for differences in
disease status at the start of the therapy, including disease
duration and functional ability, these differences were no lon-
ger significant, perhaps indicating a group of patients with
more resistant disease overall. These results are supported by
Fig. 2 Drug survival curve comparison between the MTX users versus
non-users. a Comparison among the first-line TCZ users. b Comparison
among the subsequent-line TCZ users
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those of a Japanese post-marketing surveillance which sug-
gested that longer than 10-year disease duration and advanced
disease (defined using Steinbrocker stage and class) were fac-
tors influencing lower treatment response at 28 weeks [10]. A
further observational study also suggested that previous
bDMARD exposure was not a significant predictor of treat-
ment response of TCZ at month 6 [12], although there still
remains a possibility that this difference did not reach statisti-
cal significance because of the small number of the first-line
TCZ users.
In the UK, TCZ is also approved for use as monotherapy
without MTX [5]. We did not see any difference in the influ-
ence of concurrent use of MTX on treatment response among
the TCZ users, either as a first-line or subsequent-line biolog-
ic, which differs from that reported for TNFi [33]. While the
evidence has suggested that TNFi may be more effective
when used in combination with MTX, the observed benefits
of concurrent MTX with TNFi are not well explained. In part,
it may relate to factors associated with general patient drug
tolerance and/or adherence. Studies also support a possible
role for MTX in preventing anti-drug antibodies [34], al-
though this area has been less studied with TCZ. In the current
study, the sample size of the first-line TCZ users was very
small, which may have prevented detection of smaller differ-
ences between MTX users and non-users. Whether the lack of
benefit of MTX cotherapy with TCZ will still be apparent
within larger datasets or over the longer term requires further
study.
This study has a number of limitations. Firstly, the UK has
restricted access to bDMARD therapy, demanding high dis-
ease activity (DAS28 >5.2). This may inflate the baseline
assessments and affect clinical response, which may reduce
the generalisability of the findings to other countries.
However, the observed channelling of some patients towards
treatments based on their comorbidity profile is less likely to
differ between populations, and therefore, the treatment effec-
tiveness data of this study could apply to patients with high
disease activity in other countries.
Secondly, DAS28 was used as a primary treatment effec-
tiveness measure. The DAS28 score might overestimate treat-
ment effectiveness of TCZ due to the suppression of acute
phase reactants, which may explain in part the greater lower-
ing of ESR among patients receiving TCZ compared to TNFi.
TCZ blocks IL-6 binding to its receptor, thereby preventing
IL-6-mediated signal transduction, which alters the normalis-
ing of inflammatory markers (ESR and CRP) [35]. Several
studies have reported that there is a discrepancy between
DAS28 remission and Clinical Disease Activity Index
(CDAI) remission (which does not include an acute-phase
reactant component) [35–37]. Kawashiri et al. recommended
that CDAI should be used as a disease activity measure for
TCZ users [36]. However, the BSRBR-RA did not collect
physician global assessment, a component of CDAI.
Additionally, although DAS28-CRP tends to be lower than
DAS-ESR and lower remission criteria are suggested [38],
we were unable to distinguish DAS28-ESR and DAS28-
CRP in the BSRBR-RA cohort, as the data were not always
captured. However, in this study, other than DAS28, the drug
survival curves and functional activity were also assessed as a
measure of treatment effectiveness and did not identify any
difference between treatments. Thirdly, this study might be
affected by incomplete data. In approximately 20% of pa-
tients, the 6-month disease activity and HAQ data were miss-
ing, which is common in large observational longitudinal
studies. To minimise response bias and attrition bias, multiple
imputation model was used in this study. However, the effects
of residual or unmeasured confounding factors could not be
avoided. Although we compared the changes in disease activ-
ity and disability between therapies and therapy regimens, we
did not compare the rates of adverse events. The ACT-RAY
study did suggest a non-significant increase in the occurrence
of raised liver enzymes among patients receiving TCZ in com-
bination with MTX [14]. This study focused on short-term
outcomes, but as further follow-up is accrued, future studies
should look at the longer-term tolerability and maintenance of
effect, including the risk of adverse events. It would also be
interesting to assess the effectiveness of subsequent
bDMARDs after primary failure with TCZ therapy.
Although a recent retrospective study suggested that TNFi
could be superior than abatacept for the patients showing in-
adequate response to TCZ [39], there has been sparse evi-
dence in the bDMARD selection after TCZ. Our data suggest
that any study of comparative drug safety or long-term toler-
ability must also take into account differences in the propor-
tions of baseline comorbidities, particularly pulmonary
disease.
In conclusion, this national cohort study of real-world TCZ
use has shown that with an expanding choice of therapies for
patients who are sDMARD inadequate responders, similar
improvements in disease activity and disability are seen be-
tween patients starting either TCZ or TNFi, with the exception
of a greater improvement in ESR among TCZ users. The
proportion of responders among patients who start TCZ fol-
lowing an inadequate response to one or more previous bio-
logic therapies is lower compared to first-line use but may
largely be explained by differences in disease severity. The
benefit of MTX cotherapy with TCZ was not apparent in this
study; however, this may be underestimated because of the
very small sample size of the first-line TCZ cohort.
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